| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Frazier Life Sciences Public Fund, L.P. | 11.7% | -13.6% | $72,562,680 | +$9,264,602 | 5,224,095 | +14.6% | Patrick J. Heron | 26 Sep 2025 |
| WELLINGTON MANAGEMENT GROUP LLP | 10.8% | +57.1% | $84,412,239 | +$44,744,435 | 4,823,336 | +113% | Wellington Management Group LLP | 30 Sep 2025 |
| ORBIMED ADVISORS LLC | 9% | $55,600,100 | 4,002,887 | ORBIMED ADVISORS LLC | 26 Sep 2025 | |||
| New Enterprise Associates 17, L.P. | 8.1% | $63,340,795 | 3,619,474 | Edward T. Mathers | 06 Nov 2025 | |||
| Deep Track Capital, LP | 6.55% | $28,604,897 | 2,188,592 | Deep Track Capital, LP | 30 Jun 2025 | |||
| Norwest Venture Partners XVI, LP | 4.8% | $29,738,337 | 2,140,989 | Tiba Aynechi | 26 Sep 2025 | |||
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 4.5% | $35,304,395 | 2,017,394 | Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. | 30 Sep 2025 | |||
| Hawryluk P. Kent | 4.3% | $34,925,782 | 1,995,759 | P. Kent Hawryluk | 30 Sep 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 47,790,065 | $836,364,494 | +$203,956,820 | $17.50 | 117 |
| 2025 Q2 | 36,839,365 | $420,338,016 | +$15,667,999 | $11.41 | 87 |
| 2025 Q1 | 35,666,401 | $263,219,997 | +$14,436,597 | $7.38 | 79 |
| 2024 Q4 | 32,941,714 | $606,485,118 | +$45,787,522 | $18.43 | 63 |
| 2024 Q3 | 30,305,441 | $784,071,713 | +$784,024,689 | $25.98 | 45 |